An Open-Label Phase I/II Study of TAK-700 in Combination with Docetaxel and Prednisone

C21003: An Open-Label Phase I/II Study of TAK-700 in Combination with Docetaxel and Prednisone in Men with Metastatic Castration-Resistant Prostate Cancer

Sponsor(s)

Millennium Pharma

Principal Investigator(s)Omer Kucuk, MD
Dates3/23/2011 - 3/23/2015